Abeona Therapeutics Inc vs AGCO Corporation — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while AGCO Corporation trades at $100.3 (market cap $7.10B). The key difference: AGCO Corporation is far larger — about 16.9× Abeona Therapeutics Inc's market cap, and AGCO Corporation pays a 1.18% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AGCO | |
|---|---|---|
Market Cap | $421.19M | $7.10B |
Sector | Health | Industrials |
52-Week High | $7.45 | $140.49 |
52-Week Low | $4.17 | $100.14 |
Enterprise Value | $276.10M | $9.37B |
Dividend Yield | — | 1.18% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
AGCO Corporation (NYSE: AGCO) is trading at $100.87, down 1.91% on the day, following disappointing Q2 2026 earnings that missed expectations. The agricultural equipment manufacturer faces bearish technical signals with support at $99 and resistance at $103. Fundamentally, the company maintains reasonable valuation metrics (P/E 14.03, P/S 0.72) despite recent earnings volatility, with 2025 revenue of $10.08 billion and net income of $726.5 million. Recent leadership changes and multiple securities investigations have created investor uncertainty.
The outlook remains cautious as AGCO navigates weaker industry demand and lowered 2026 guidance. While analyst consensus suggests 23.5% upside to the $124.63 price target, near-term headwinds from agricultural market softness and legal scrutiny present significant risks. The stock's current valuation may offer value for patient investors, but execution risks and market sentiment require careful monitoring.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →